Oxford Biomedica PLC Board Change (0326O)
27 Janvier 2023 - 8:00AM
UK Regulatory
TIDMOXB
RNS Number : 0326O
Oxford Biomedica PLC
27 January 2023
Board Change
Oxford, UK - 27 January 2023: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Company"), a leading gene and cell
therapy group, today announces a change to the Group's Board of
Directors.
Dr. Siyamak ("Sam") Rasty has informed the Board that he will
not be standing for re-election at the Company's AGM in June 2023.
Sam joined the Board in December 2020 and is a member of the
Scientific and Technology Advisory Committee and was a member of
the Audit Committee until December 2021.
Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica,
commented: " It has been a pleasure to have Dr. Sam Rasty on the
Board. His extensive experience in biopharma R&D and in
building and growing successful gene therapy companies has been a
valuable asset to Oxford Biomedica. As we focus on our
innovation-led CDMO business, I would like to express my thanks for
his service to the Company, in particular his contribution to our
work in externalising our therapeutics business, which is
progressing well, and wish him well for the future."
Dr. Sam Rasty, Non-Executive Director of Oxford Biomedica added:
" I am honoured to have had the opportunity to serve on the Board
of Oxford Biomedica and assist the Company as it has grown to
become a world leader in viral vectors. I wish the team continued
success in the future as Oxford Biomedica focuses on becoming a
world-class, innovation-led CDMO."
-Ends-
Enquiries:
Oxford Biomedica plc:
Stuart Paynter, Chief Financial Officer - T: +44 (0)1865 783
000
Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488 / E:
ir@oxb.com
Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394
562 425 / E: ir@oxb.com
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E:
oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Cole / Angela Gray
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector
specialist focused on delivering life changing therapies to
patients.
Oxford Biomedica plc and its subsidiaries (the Group) work
across key viral vector delivery systems including those based on
lentivirus, adeno-associated virus (AAV) and adenovirus, providing
innovative solutions to cell and gene therapy biotechnology and
biopharma companies for their process development, analytical
development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector(R)
platform, and is working on programmes from pre-clinical to
commercial stage across a range of therapeutic areas with global
partners.
Oxford Biomedica is based across several locations and
headquartered in Oxfordshire, UK. In 2022, the Group established
Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing
and innovation business, based near Boston, US.
Further information is available at www.oxb.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOANKABBCBKDDDB
(END) Dow Jones Newswires
January 27, 2023 02:00 ET (07:00 GMT)
Oxford Biomedica (AQSE:OXB.GB)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Oxford Biomedica (AQSE:OXB.GB)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024